SpringerLink
Log in

Personalise treatment for rosacea by selecting from a range of options for individual features

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Rosacea is a chronic, inflammatory condition of facial skin. Treatment of rosacea should be based on its presenting features i.e. inflammatory lesions, erythema, phymas and/or telangiectasia. First-line treatment options for inflammatory lesions include metronidazole, azelaic acid, ivermectin and modified-release doxycycline, but topical formulations of minocycline foam and encapsulated benzoyl peroxide are also now available. Persistent erythema can be treated with topical α-adrenergic receptor agonists or light-based therapies. Approved pharmacological options for phymas and telangiectasia are limited; nonpharmacological procedures should be considered in some cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501–10.

    Article  PubMed  Google Scholar 

  2. Korting HC, Schollmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009;23(8):876–82.

    Article  CAS  PubMed  Google Scholar 

  3. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea Consensus 2019 panel. Br J Dermatol. 2020;182(5):1269–76.

    Article  CAS  PubMed  Google Scholar 

  4. Desai SR, Baldwin H, Del Rosso JQ, et al. Microencapsulated benzoyl peroxide for rosacea in context: a review of the current treatment landscape. Drugs. 2024;84(3):275–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Choe J, Barbieri JS. Emerging medical therapies in rosacea: a narrative review. Dermatol Therapy. 2023;13(12):2933–49.

    Article  Google Scholar 

  6. Williamson T, Kamalakar R, Ogbonnaya A, et al. Rate of adverse events and healthcare costs associated with the topical treatment of rosacea. Am Health Drug Benefits. 2017;10(3):113–9.

    PubMed  PubMed Central  Google Scholar 

  7. Webster G, Schaller M, Tan J, et al. Defining treatment success in rosacea as “clear” may provide multiple patient benefits: results of a pooled analysis. J Dermatolog Treat. 2017;28(5):469–74.

    Article  PubMed  Google Scholar 

  8. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123(5):609–14.

    Article  CAS  PubMed  Google Scholar 

  9. Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65–79.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45(5):723–30.

    Article  CAS  PubMed  Google Scholar 

  11. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836–45.

    Article  PubMed  Google Scholar 

  12. Draelos ZD, Elewski BE, Harper JC, et al. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015;96(1):54–61.

    PubMed  Google Scholar 

  13. Stein Gold L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316–23.

    Google Scholar 

  14. Stein Gold L, Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82(5):1166–73.

    Article  Google Scholar 

  15. Bhatia ND, Werschler WP, Baldwin H, et al. Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from two phase III, randomized, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):34–40.

    PubMed  PubMed Central  Google Scholar 

  16. Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad of Dermatol. 2007;56(5):791–802.

    Article  Google Scholar 

  17. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134(6):679–83.

    Article  CAS  PubMed  Google Scholar 

  18. Stein Gold L, Kircik L, Fowler J, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13(11):1380–6.

    PubMed  Google Scholar 

  19. Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103–10.

    Article  CAS  PubMed  Google Scholar 

  20. Siddiqui K, Stein Gold L, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. Springerplus. 2016;5(1):1151.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Elewski BE, Fleischer AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444–50.

    Article  CAS  PubMed  Google Scholar 

  22. Stein Gold L, Rosso JQ, Kircik L, et al. Open-label extension study evaluating long-term safety and efficacy of FMX103 1.5% minocycline topical foam for the treatment of moderate-to-severe papulopustular rosacea. J Clin Aesthet Dermatol. 2020;13(11):44–9.

    PubMed  PubMed Central  Google Scholar 

  23. Werschler WP, Sugarman J, Bhatia N, et al. Long-term efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from an extension of two phase III, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):27–33.

    PubMed  PubMed Central  Google Scholar 

  24. Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573–6.

  25. Rosso JQ, Brantman S, Baldwin H. Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily. Dermatol Ther. 2022;35(1): e15180.

    PubMed  Google Scholar 

  26. Thiboutot DM, Fleischer AB, Del Rosso JQ, et al. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639–48.

    PubMed  Google Scholar 

  27. Schaller M, Kemeny L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336–43.

    Article  CAS  PubMed  Google Scholar 

  28. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9(6):607–13.

    PubMed  Google Scholar 

  29. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641–5.

    PubMed  Google Scholar 

  30. Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56–61.

    CAS  PubMed  Google Scholar 

  31. Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78(6):1156–63.

    Article  CAS  PubMed  Google Scholar 

  32. Fowler J, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650–6.

    CAS  PubMed  Google Scholar 

  33. Tanghetti EA, Jackson JM, Belasco KT, et al. Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2015;14(1):33–40.

    CAS  PubMed  Google Scholar 

  34. Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol. 2018;17(1):97–105.

    PubMed  Google Scholar 

  35. Baumann L, Goldberg DJ, Stein Gold L, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial. J Drugs Dermatol. 2018;17(3):290–8.

    PubMed  Google Scholar 

  36. Kaufman BP, Aman T, Alexis AF. Postinflammatory hyperpigmentation: epidemiology, clinical presentation, pathogenesis and treatment. Am J Clin Dermatol. 2018;19(4):489–503.

    Article  PubMed  Google Scholar 

Download references

Funding

The preparation of this review was not supported by any external funding.

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Tina Nie

Authors
  1. Tina Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina Nie.

Ethics declarations

Authorship and Conflict of Interest

T. Nie is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics Approval, Consent to Participate, Consent for Publication, Availability of Data and Material, Code Availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, T. Personalise treatment for rosacea by selecting from a range of options for individual features. Drugs Ther Perspect (2024). https://doi.org/10.1007/s40267-024-01081-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40267-024-01081-w

Search

Navigation